|By PR Newswire||
|September 2, 2014 03:15 PM EDT||
NEW YORK, Sept. 2, 2014 /PRNewswire-USNewswire/ -- The cover story of the September 2014 edition of Chemical and Engineering News, titled "Aiming for HIV's Weak Spot," cites work by NYBC's Asim Debnath, Ph.D., and his Laboratory of Molecular Modeling and Drug Design for their work to identify small molecules that prevent HIV from entering T cells.
Here's a link to the story:
Dr. Debnath's lab was the first to discover the two inhibitors, known as NBD-556 and NBD-557. High-throughput screening was used to identify the HIV-blocking molecules, which came to be known as gp 120 targeted entry inhibitors.
Since this discovery in 2005, the lab has deepened its HIV investigations, as have research colleagues from Harvard, the University of Pennsylvania, Johns Hopkins, Drexel, and others.
Debnath's team recently developed a small molecule based on what they've gleaned from NBD-556 and related compounds over the years. "It has extraordinary breadth of antiviral activity among inhibitors of this class reported so far," and it does not promote HIV entry to cells, he says. Debnath hopes to publish the work in the next few months.
The Laboratory of Molecular Modeling and Drug Design's current work on inhibitors is supported by a five-year grant from the National Institutes of Health (NIH).
About Lindsley F. Kimball Research Institute: Since 1964, LFKRI has led the way in blood research, breaking new ground in transfusion medicine and disease treatment and prevention. The institute is committed to furthering research efforts that support the discovery of new blood-related products, techniques, and therapies. LFKRI's work has dramatically impacted global health, improved blood banking, nurtured a generation of scientists, and added significantly to the world's store of biomedical knowledge. From the beginning, LFKRI has supported basic research to understand blood and disease at the molecular level as well as translational research that transforms the findings into major breakthroughs. With 17 state-of-the-art laboratories and close to 100 researchers, LFKRI brings world-class research to life every day. For further information, visit http://www.nybloodcenter.org/lfkri.do?sid0=64
About New York Blood Center: New York Blood Center (NYBC) is one of the nation's largest non-profit, community-based blood centers. For 50 years, NYBC has been providing blood, transfusion products and services to hospitals serving more than 20 million people in New York City, Long Island, the HudsonValley, New Jersey, and parts of Connecticut and Pennsylvania. NYBC is also home to the Lindsley F. Kimball Research Institute and the National Cord Blood Program, the world's largest public cord blood bank. NYBC provides medical services and programs (Clinical, Transfusion, and Hemophilia Services) through our medical professionals along with consultative services in transfusion medicine. Please visit us on Facebook at www.Facebook.com/newyorkbloodcenter. Follow us on Twitter: @NY_BloodCenter. Website: www.nybloodcenter.org.
Contact: Victoria O'Neill, 212-683-8100, [email protected]
SOURCE New York Blood Center
Jul. 26, 2016 01:45 PM EDT Reads: 1,988
Jul. 26, 2016 12:30 PM EDT Reads: 1,576
Jul. 26, 2016 11:45 AM EDT Reads: 547
Jul. 26, 2016 10:45 AM EDT Reads: 1,715
Jul. 26, 2016 10:37 AM EDT Reads: 278
Jul. 26, 2016 10:15 AM EDT Reads: 1,179
Jul. 26, 2016 10:00 AM EDT Reads: 986
Jul. 26, 2016 09:45 AM EDT Reads: 934
Jul. 26, 2016 09:45 AM EDT Reads: 765
Jul. 26, 2016 09:45 AM EDT Reads: 333
Jul. 26, 2016 09:30 AM EDT Reads: 1,076
Jul. 26, 2016 09:15 AM EDT Reads: 1,010
Amazon has gradually rolled out parts of its IoT offerings in the last year, but these are just the tip of the iceberg. In addition to optimizing their back-end AWS offerings, Amazon is laying the ground work to be a major force in IoT – especially in the connected home and office. Amazon is extending its reach by building on its dominant Cloud IoT platform, its Dash Button strategy, recently announced Replenishment Services, the Echo/Alexa voice recognition control platform, the 6-7 strategic...
Jul. 26, 2016 09:02 AM EDT Reads: 242
Ovum, a leading technology analyst firm, has published an in-depth report, Ovum Decision Matrix: Selecting a DevOps Release Management Solution, 2016–17. The report focuses on the automation aspects of DevOps, Release Management and compares solutions from the leading vendors.
Jul. 26, 2016 09:00 AM EDT Reads: 1,694
Continuous testing helps bridge the gap between developing quickly and maintaining high quality products. But to implement continuous testing, CTOs must take a strategic approach to building a testing infrastructure and toolset that empowers their team to move fast. Download our guide to laying the groundwork for a scalable continuous testing strategy.
Jul. 26, 2016 09:00 AM EDT Reads: 1,956